What Angedil Treats: Main Uses and Benefits

Angedil is commonly used in the symptomatic management of stable angina pectoris. It is applied across domains where additional symptomatic support is needed to help address symptoms related to physical discomfort and heightened physiological activity.

The medication is relevant for easing the recurrent, episodic manifestations of angina, such as chest discomfort, pressure, or heaviness linked to organ-specific functional stress. This treatment is also helpful in situations where symptom clusters may become intense or disruptive, particularly when symptoms interfere with daily functioning.

The medication is generally applied during phases when symptoms become more noticeable, offering supportive relief that helps patients cope more steadily with symptom fluctuations. This contributes to improved comfort during symptomatic periods.

---

Quick Fact: Support for Angina Symptoms
Used in: Conditions characterized by periods of heightened symptoms.
Main Benefit: May assist with easing the overall symptom burden.

Official Eligibility and Contraindications

Angedil (Nicorandil) is officially established for use exclusively in adult patients (aged 18 and over). Regulatory documents define specific groups who must not use the medicine, as well as populations requiring conditional use or exclusion due to unestablished safety.

Classification	Population or Condition
Absolute Contraindication	Cardiogenic shock, severe hypotension, hypovolaemia, or acute pulmonary oedema.
	Patients with known hypersensitivity to Nicorandil or excipients.
	Concurrent use with Phosphodiesterase 5 (PDE5) inhibitors (e.g., sildenafil) or soluble Guanylate Cyclase (sGC) stimulators (e.g., riociguat).
Not Recommended	Children and Adolescents (under 18 years) due to unestablished safety and efficacy.
	Pregnancy and Lactation (Breastfeeding).
Conditional Use (Caution)	Patients with very low systolic blood pressure (e.g., below 100 mmHg).
	Patients with Diverticular Disease or severe Heart Failure (NYHA Class III or IV).

Eligibility is maintained for older adults, with the general recommendation to use the lowest effective dose. Similarly, no special dose requirements are typically needed for patients with hepatic (liver) or renal (kidney) impairment.

Angedil Interactions with other medicines and products

Official regulatory documents detail specific drug combinations and substance classes that interact with Angedil (Nicorandil). These interactions mainly stem from its dual action as a potent vasodilator.

Contraindicated Combinations

The co-administration of Nicorandil with the following is strictly prohibited (contraindicated) due to the risk of severe, life-threatening hypotension (serious drop in blood pressure):

Classification	Examples	Risk Statement
Phosphodiesterase 5 (PDE5) Inhibitors	Sildenafil, Tadalafil, Vardenafil	Serious fall in blood pressure
Soluble Guanylate Cyclase (sGC) Stimulators	Riociguat	Serious fall in blood pressure

---

Use with Caution

The simultaneous use of Nicorandil with other agents that lower blood pressure, including antihypertensive agents, other vasodilators, or tricyclic antidepressants, may potentiate the hypotensive effect.

There is an officially documented increased risk of severe gastrointestinal complications (ulceration, perforation, haemorrhage) when Nicorandil is used alongside Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or Corticosteroids.

Caution is also required when using medicinal products that may increase potassium levels, especially in patients with moderate to severe renal impairment, due to the risk of Hyperkalaemia.

Metabolism and Non-Medicinal Interactions

Official studies show that Nicorandil's metabolism is not significantly affected by the CYP inhibitor Cimetidine or the CYP3A4 inducer Rifampicin. However, the blood pressure lowering effect may be increased by alcohol. While food may delay Nicorandil's absorption rate, it does not alter the total amount absorbed.

Dual Modulation of Vascular Smooth Muscle

Angedil functions via two simultaneous pathways: the Potassium Channel (KATP) Activation and Nitric Oxide (NO) Donation. The KATP activation induces arterial relaxation by electrically hyperpolarizing vascular cells and inhibiting calcium entry, which induces a decrease in systemic vascular resistance (afterload). Concurrently, NO release activates the sGC-cGMP cascade, causing venodilation that reduces venous return, resulting in a decrease in venous return (preload).

---

Myocardial Cellular Modulation

Activation of mitochondrial KATP channels (mKATP) inside heart muscle cells induces a change in mitochondrial membrane potential that structurally mimics ischemic preconditioning. This KATP component of the mechanism is not associated with the functional limitation of nitrate tolerance and contributes to the overall modulation of hemodynamics. This dual mechanism results in a balanced physiological modulation of the myocardial oxygen supply-to-demand ratio.

How to Use Angedil

Angedil (Nicorandil) is administered exclusively via the oral route as a scored tablet for the long-term management of the intended condition. The medicine is designed to be taken twice daily (bid), preferably scheduled for the morning and evening, a pattern essential for maintaining a consistent presence of the drug in the body. Administration is independent of food intake.

---

Dosing and Adjustment

The standard approach to treatment begins with a 10 mg dose taken twice daily. However, a lower 5 mg starting dose may be used for individuals who are particularly sensitive to initial reactions. The tablet is scored to facilitate the preparation of this lower dose. Dosage is subsequently titrated upwards according to clinical needs and patient tolerance, within the usual therapeutic range of 10 mg to 20 mg twice daily. The maximum dose officially recommended for use is 40 mg taken twice daily.

---

Procedural Instructions

For proper use, the tablet must be swallowed whole with a glass of water and should not be crushed or chewed. This is a crucial procedural constraint related to how the medicine is intended to be absorbed. If a scheduled dose is missed, it should be taken as soon as the timing is realized, unless it is nearly time for the next dose, in which case the missed dose must be skipped; do not take a double dose. Treatment discontinuation should involve a gradual dosage reduction and is not advised to be abrupt.

---

Population-Specific Usage

Nicorandil is not recommended for the paediatric population as safety and efficacy have not been established. For older adults, the use of the lowest effective dose is advised, but no specific mandatory dosage adjustment is prescribed. Similarly, no dedicated dosage adjustments are required for patients with either renal or hepatic impairment.

Research Evidence / Overview of Studies for Angedil

---

Evidence for Symptomatic Relief in Chronic Stable Angina

Research exploring Angedil (Nicorandil) has centered on its use in adults diagnosed with chronic stable angina pectoris. Many short-term randomized controlled trials (RCTs) and comparative trials have been conducted, often including other established antianginal drugs as comparators. This research examined patient-reported experiences of chest pain and evaluated outcomes reflecting daily functioning or activity level.

In these trials, researchers monitored outcomes related to physical discomfort, such as angina attack frequency and exercise duration. Data show patterns related to changes measured in these areas were generally similar across study groups observed over short periods (typically five to six weeks). However, the duration of these symptom-relief studies was limited, and research generally does not show greater differences in measured outcomes compared to other standard pharmacological approaches studied for this indication.

---

Evidence for Long-Term Outcomes in High-Risk Patients

Beyond symptom measurements, a large, dedicated, long-term, placebo-controlled RCT was conducted to observe long-term outcomes for a specific group of high-risk patients with stable angina who were receiving standard treatment. This research followed patients for an average of over a year, tracking a composite measure of serious cardiovascular events.

In this highly specific, high-risk population (including patients with prior heart attacks or diabetes), the research describes patterns related to a lower observed incidence of the combined endpoint in the groups receiving Angedil compared to those receiving a placebo. The analysis reported that these findings showed the greatest contribution from observations regarding unplanned hospitalizations for cardiac chest pain. Results apply only to the populations studied, providing limited insight into the long-term patterns for lower-risk individuals.

---

What is Still Uncertain About Angedil's Research Profile

The existing research indicates several areas where knowledge remains limited or findings were mixed. The certainty remains low regarding the long-term effects on day-to-day symptom management beyond a year, particularly in average-risk patients. Furthermore, data for certain groups remain insufficient, such as pediatric populations, as they were often excluded from the larger clinical trials. The overall research highlights what is known—and what is still uncertain—about Angedil.

Common questions about Angedil (FAQ)

---

Q: What are the main or most frequent side effects I might experience when starting Angedil?

Official product information states that the most common side effect is headache, which can affect more than 1 in 10 people (Very Common), especially when treatment is first started. Other commonly reported effects include dizziness and flushing (a sensation of warmth). These effects are typically temporary.

---

Q: How should I stop taking Angedil treatment?

Patients are advised not to stop taking this medicine or change the dose without first consulting a healthcare provider. Official guidance indicates that treatment discontinuation requires a gradual dosage reduction and is not advised to be abrupt. This gradual process is required to ensure proper medical supervision.

---

Q: What class of medicine is Nicorandil, and how does it work to help my heart?

Nicorandil is a hybrid antianginal medicine classified as a potassium channel activator and a nitric oxide donor. This dual mechanism is designed to improve blood flow and oxygen supply to the heart muscle while reducing the heart's overall workload. Its action is intended for the management of chronic stable angina.

---

Q: What temperature should I store my Angedil tablets at, and how long are they good for once I open the packaging?

Official storage requirements specify that Angedil tablets should be kept at a stable room temperature, not exceeding 25 C (77°F). The drug must be kept in its original blister pack for protection from light and moisture. Once an individual blister strip is opened, the tablets within that strip must be used within 30 days.

---

Q: Can I cut or crush the Angedil tablets to make them easier to swallow?

Regulatory guidance specifies that the tablets should be swallowed whole with liquid and are not intended to be crushed or chewed. Although the tablet is scored, which permits breaking it into two equal halves for dose adjustment, this must be done only under the direction of a healthcare provider.

---

Q: Is there any risk of developing a tolerance to the effects of Nicorandil over time?

Regulatory reviews and clinical literature generally indicate that Nicorandil is not associated with developing tolerance over time. This indicates that the risk of tolerance developing is low.

---

Q: What should I do if my blood pressure drops very low while taking Angedil?

If signs of very low blood pressure (hypotension), such as feeling lightheaded, dizzy, or weak, are experienced, immediate medical assistance should be sought. The official product information advises that if the blood pressure drops significantly, or if the heart rate speeds up substantially, a patient should contact an emergency line or go to the nearest emergency department.

Official Storage and Disposal Requirements

Storage Classification	Requirement
Temperature Limit	Do not store above 25 C
Protection Mandate	Store in the original package to protect from moisture and light.
In-use Stability	Tablets in the opened blister strip must be used within 30 days.
Child Safety	Keep the medicine out of the sight and reach of children.
Disposal Rule	Dispose of unused product in accordance with local requirements; do not throw away via wastewater or household waste.

The regulatory labeling dictates that Angedil must be stored at a stable room temperature, not exceeding 25 C. Due to the drug's sensitivity, it must remain in its original, sealed blister packaging to prevent moisture exposure, with a mandatory 30-day limit for use once the strip is opened. For safety, the product must be kept away from children. Official disposal instructions prohibit discarding the medicine in household waste and require that unused portions be handled via appropriate local collection schemes, such as a pharmacy take-back program.